Shares of Cambridge biotech plunge as postpartum drug fails late-stage trial

//Shares of Cambridge biotech plunge as postpartum drug fails late-stage trial

Shares of Cambridge biotech plunge as postpartum drug fails late-stage trial

One of the biotech industry’s emerging neuroscience companies, Sage Therapeutics, disclosed Thursday that one of its most promising potential products failed a late-stage study. The Cambridge-company's shares fell by more than half on Thursday morning, shaving more than $3 billion off its market value. Sage (Nasdaq: SAGE) has become one of the area biotech industry’s most closely watched companies through its work on postpartum depression and other psychiatric disorders. It has consistently…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2019-12-05T14:54:00+00:00 December 5th, 2019|Healthcare|

About the Author: